Birch Bark Extract: A Review in Epidermolysis Bullosa

Area of Science:

• Dermatology
• Wound Healing
• Rare Diseases

Background:

• Epidermolysis bullosa (EB) is a group of rare genetic disorders characterized by fragile skin prone to blistering and wounds.
• Current treatment options for EB-associated wounds are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of birch bark extract (Filsuvez) for treating partial thickness wounds in patients with dystrophic and junctional epidermolysis bullosa.
• To assess the long-term clinical benefits and tolerability of birch bark extract in EB patients.

Main Methods:

• A pivotal, double-blind, randomized, vehicle-controlled, phase III EASE trial was conducted in patients aged 6 months and older with EB.
• Patients received either birch bark extract (Filsuvez) or a control gel, with the primary endpoint being the proportion of patients achieving first complete target wound closure within 45 days.

Main Results:

• The primary endpoint was met, demonstrating a significantly higher proportion of patients achieving complete wound closure with birch bark extract compared to the control gel.
• Birch bark extract treatment also showed improvements in wound burden and associated symptoms.
• Benefits were maintained during a 24-month open-label extension period, and the treatment was well-tolerated.

Conclusions:

• Birch bark extract (Filsuvez) is an effective and emerging treatment for partial thickness wounds in patients with dystrophic and junctional EB.
• The therapy offers sustained clinical benefits and a favorable tolerability profile, representing a significant advancement in EB wound care.